FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to production of highly glycated fused proteins based on human blood coagulation factor VIII (FVIII), and can be used in medicine for preventing or treating haemorrhagic diseases in FVIII deficient patients. Disclosed homodimer fusion protein consists of, successively from N- to C-end, a human coagulation factor VIII, a flexible peptide linker, at least one rigid carboxy-terminal peptide link of human chorionic gonadotropin beta-subunit and human immunoglobulin Fc-fragment.
EFFECT: invention enables to obtain a protein with a level of biological activity similar to the level of recombinant FVIII, and an extended half-life in vivo, that is FVIII-based drug with improved pharmacokinetics and efficacy.
11 cl, 5 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| BISPECIFIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2787783C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
